MRFF - 2019 Ovarian Cancer Research



Notice of Intent (NOI) registration OPEN

10am, 13 Jan 2020 (Monday)

Draft Grant Proposal due to RIC for strategic review. Early submission encouraged.

5pm, 22 Jan 2020 (Wednesday)

Draft application due to RIC for compliance and eligibility check

5pm, 22 Jan 2020 (Wednesday)

Minimum Data due on RGMS

5pm, 3 Feb 2020 (Monday)

Authority to Submit due to RIC

10am, 3 Feb 2020 (Monday)

Final application submitted to RIC

5pm, 5 Feb 2020 (Wednesday)

Final application submitted to NHMRC


The Ovarian Cancer Research Grant Opportunity is part of the MRFF Emerging Priorities and Consumer Driven Research (EPCDR) initiatives. The objectives of the Ovarian Cancer Research Grant Opportunity are to:

− facilitate innovative, high quality research that will lead to:

  • improved diagnosis and treatment of ovarian cancer
  • research that will address the gaps in research, leading to a better understanding of the causes and underlying factors that contribute to the development and progression of ovarian cancer.

− facilitate consumer involvement in the design and evaluation of the research project (including participation in the conduct of the research)

− provide high-quality evidence for new health treatments and/or drugs (where appropriate) − enable rapid translation of consumer-relevant research into clinical practice, health policy, and/or health advice that will lead to positive impacts for consumers

− encourage the development of multi-disciplinary research teams that deliver measureable outcomes that are a priority for consumers

− encourage collaboration between research teams, policy makers, healthcare funders and the health delivery sector (e.g. education, community, industry and/or healthcare).

Research under this grant opportunity could include (but is not limited to) the following areas:

− Biology and aetiology (basic science, mechanisms of resistance and recurrence, aetiology)

− Inherent and acquired drug resistance

− Drug repurposing

− Experimental models (preclinical models, in vitro models) Epidemiology and prevention (risk, epidemiology, surgical methods, other)

− Detection pathways to earlier diagnosis, diagnosis of disease subtypes

− Treatment (new treatments, improving response to existing treatments, managing side effects, radiotherapy)

− Translation of existing or completed clinical trial findings into practice

− Health services research (healthy service models/patterns of care, patient experience and patient reported outcomes, psychosocial support, quality of life, palliative care).


The Australian Government has announced a total of $633 million for the EPCDR Initiative.

For this grant opportunity, up to $20 million of funding is available from 2019-20 to 2023-24 for ovarian cancer research. There is no maximum grant amount but grants cannot exceed the amount of available funds. The maximum grant period is five years

$4.0m $4.0m $4.0m $4.0m $4.0m


- A person must not be named as a Chief Investigator (CI) on more than one application submitted to this grant opportunity. You are eligible to apply for more than one grant opportunity under the same EPCDR initiatives.

- You are not eligible if your research proposal was submitted to the MRFF International Clinical Trial Collaboration (ICTC) Program and it is currently being assessed, or is included in the ICTC Merit List. Chief Investigators on an application submitted to the ICTC Program that is currently being assessed or is included in the ICTC Merit List are eligible to submit a different research proposal to this grant opportunity.

- The proposed research should not duplicate research previously or currently being undertaken. The NHMRC may compare the research proposed in grant applications with grants previously or currently funded by the MRFF, NHMRC or other agencies (e.g. Australian Research Council) and published research (see also section 4.7 – Other ineligible expenditure)

How to apply

  1. Notice of Intent: Please register your Notice of Intent if you are considering applying for the MRFF RCRDUN.  RIC-MRFF team will then contact each applicant with further information.
  2. Update RGMS Profile: Each CI must obtain access to RGMS and update profile information (see RGMS information)
  3. Review documentation: Review the RCRDUN grant guidelines and Assessment Criteria Scoring Matrix below. Relevant documents can be found on Grant Connect.
  4. Create and Complete the application:  Log in to RGMS select "MRFF - Research Grant" from Initiatives and then select the relevant scheme from Round and complete the application.
  5. Submit “Review Ready” application to RIC: Submit application to RIC within the RIC internal submission period for review.
  6. Complete application: After taking feedback from the RIC team into consideration, complete the application in RGMS. It is suggested advice is sought from colleagues, Faculty Mentors, etc. before finalising the application.
  7. Submit the UoM Authority to Submit Form:
  8. This form must be submitted to RIC electronically by the final internal closing date. This form should include:

    • Complete the compliance and eligibility section
    • Signature of all CIs and AIs
    • Signature of the Head of Department for CIA

    Electronic signatures and email consent are permitted.

    This is an NHMRC requirement and the application cannot be submitted to NHMRC until received.

  9. Final Submission:
    • On the final internal closing date, the applicant must:
    • Submit finalised application by clicking ‘Submit to RAO’ in RGMS
    • Email RIC as well as a scanned, signed Authority to Submit form.
    • Should you require further information please contact Alvin Wong on 83449352 or via email
  10. RIC will submit the application: Once the application has been submitted to NHMRC, you will receive an email from RIC confirming submission.

Supporting documents

NHMRC Documents

Grant Guidelines

Assessment Criteria Scoring Matrix

Rating Scale for Overall Value and Risk

Grant Proposal Template

Minimum Data

RIC Documents

Summary and Tips

Authority to Submit

Wording for written consent


MRFF Ovarian Cancer questions and primary email

Key Contacts

Alvin Wong and Catherine Nobes
T: +61 3 8344 9352 (Alvin) T: +61 3 8344 1471 (Catherine)